| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| K1034 |
Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count |
12,992 |
11,196 |
$885K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
14,130 |
12,996 |
$621K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
2,636 |
2,362 |
$528K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
5,898 |
5,649 |
$293K |
| 87529 |
|
2,292 |
2,055 |
$102K |
| 87481 |
|
2,105 |
1,882 |
$72K |
| 87563 |
|
2,041 |
1,827 |
$62K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
2,291 |
2,053 |
$52K |
| 87640 |
|
2,413 |
2,166 |
$51K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
2,289 |
2,050 |
$47K |
| 87653 |
|
2,086 |
1,870 |
$47K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
2,206 |
1,971 |
$31K |
| 87511 |
|
2,298 |
2,055 |
$29K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
1,329 |
1,205 |
$27K |
| 81514 |
|
751 |
565 |
$26K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
1,598 |
1,440 |
$25K |
| 81025 |
|
4,180 |
3,888 |
$17K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
253 |
231 |
$16K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
336 |
295 |
$15K |
| 87581 |
|
395 |
368 |
$9K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
1,071 |
634 |
$8K |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
139 |
135 |
$7K |
| 87498 |
|
281 |
257 |
$6K |
| 87486 |
|
281 |
257 |
$6K |
| 81003 |
|
4,900 |
4,511 |
$6K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
123 |
117 |
$5K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
147 |
140 |
$3K |
| 87541 |
|
145 |
128 |
$3K |
| 87641 |
|
145 |
128 |
$3K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
318 |
288 |
$3K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
78 |
78 |
$2K |
| 87634 |
|
320 |
294 |
$2K |
| 81002 |
|
514 |
499 |
$997.89 |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
72 |
69 |
$818.37 |
| 99384 |
|
13 |
12 |
$700.00 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
31 |
31 |
$366.25 |
| 87088 |
|
38 |
36 |
$200.02 |
| 00000 |
|
13 |
13 |
$0.00 |